Identification of optical density ratios in subretinal fluid as a clinically relevant biomarker in exudative macular disease

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 7, 2009, Pages 3417-3424

  Ahlers, Christian ^a   Golbaz, Isabelle ^a   Einwallner, Elisa ^a   Dunavölgyi, Roman ^a   Malamos, Panagiotis ^a   Stock, Geraldine ^a   Pruente, Christian ^a   Schmidt Erfurth, Ursula ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

AGED; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD RETINA BARRIER; CASE STUDY; CENTRAL SEROUS RETINOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MALE; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL DENSITY; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL FLUID; TREATMENT OUTCOME; VISION; VISUAL ACUITY; ADULT; BODY FLUID; COMPARATIVE STUDY; DENSITOMETRY; DRUG ANTAGONISM; EXUDATE; FLUORESCENCE ANGIOGRAPHY; METABOLISM; PHYSIOLOGY; PROSPECTIVE STUDY; RETINA DISEASE; RETINA MACULA DEGENERATION; SUBRETINAL NEOVASCULARIZATION; THREE DIMENSIONAL IMAGING;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BLOOD-RETINAL BARRIER; BODY FLUIDS; CHOROIDAL NEOVASCULARIZATION; DENSITOMETRY; EXUDATES AND TRANSUDATES; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; IMAGING, THREE-DIMENSIONAL; MACULAR DEGENERATION; MALE; PROGNOSIS; PROSPECTIVE STUDIES; RETINAL DISEASES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 67649958462     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2759     Document Type: Article

References (20)

1. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992;99(6):933-943.
2. Vingerling JR, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995;102(2):205-210.
3. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol. 1988;32(6):375-413.
4. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-676.
5. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-1431.
6. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina. 2007; 27(2):133-140.
7. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of agerelated macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564-572.
8. Thylefors B. A global initiative for the elimination of avoidable blindness. Am J Ophthalmol. 1998;125(1):90-93.
9. Coleman AL, Yu F. Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999. Ophthalmology. 2008;115(1):18-25.
10. Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol. 2007;144(4):627-637.
11. Srinivasan VJ, Wojtkowski M, Witkin AJ, et al. High-definition and 3-dimensional imaging of macular pathologies with high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology. 2006;113(11):2054 e1-14.
12. Pieroni CG, Witkin AJ, Ko TH, et al. Ultrahigh resolution optical coherence tomography in non-exudative age related macular degeneration. Br J Ophthalmol. 2006;90(2):191-197.
13. Ko TH, Fujimoto JG, Schuman JS, et al. Comparison of ultrahighand standard-resolution optical coherence tomography for imaging macular pathology. Ophthalmology. 2005;112(11):1922 e1-15.
14. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143(4):566-583.
15. Ahlers C, Golbaz I, Stock G, et al. Time course of morphologic effects on different retinal compartments after ranibizumab therapy in age-related macular degeneration. Ophthalmology. 2008; 115(8):e39-46.
16. Klein ML, Van Buskirk EM, Friedman E, et al. Experience with nontreatment of central serous choroidopathy. Arch Ophthalmol. 1974;91(4):247-250.
17. Kitzmann AS, Pulido JS, Diehl NN, et al. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota 1980-2002. Ophthalmology. 2008;115(1):169-173.
18. Ojima Y, Hangai M, Sasahara M, et al. Three-dimensional imaging of the foveal photoreceptor layer in central serous chorioretinopathy using high-speed optical coherence tomography. Ophthalmology. 2007;114(12):2197-2207.
19. Barthelmes D, Sutter FK, Gillies MC. Differential optical densities of intraretinal spaces. Invest Ophthalmol Vis Sci. 2008;49(8): 3529-3534.
20. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.